Renovorx, Inc. income statement

In fiscal 2025, Renovorx, Inc. reported revenue of $1.1m, up 2511.6% on the year before, operating income of −$12.5m (a -1114.0% margin) and net income of −$11.2m, or −$0.32 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Renovorx, Inc.: income statement, annual
Fiscal year	2024Dec 2024	2025Dec 2025	LTMJun 2026
Revenue	0	1	2
Cost of revenue	0	0	0
Gross profit	0	1	2
Research and development	6	6	6
Selling, general and administrative	5	7	10
Operating income	−11	−13	−14
Income before tax	−9	−11	—
Income tax	—	0	0
Net income	−9	−11	−12
Diluted EPS	−$0.40	−$0.32	−$0.31
Diluted shares (average)	22m	35m	40m
EBITDA	−11	−11	−13

US$ thousands unless shown otherwise. Fiscal quarters.

Renovorx, Inc.: income statement, quarterly
Quarter	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026
Revenue	197	422	266	238	563	909
Cost of revenue	94	152	53	28	84	143
Gross profit	103	270	213	210	479	766
Research and development	1,642	1,426	1,685	1,501	1,228	1,200
Selling, general and administrative	1,571	1,522	1,728	2,231	2,720	2,915
Operating income	−3,110	−2,678	−3,200	−3,522	−3,469	−3,349
Income tax	0	0	0	2	0	0
Net income	−2,420	−2,895	−2,912	−2,941	−3,521	−2,911
Diluted EPS	−$0.08	−$0.08	−$0.08	−$0.08	−$0.09	−$0.06
EBITDA	−3,109	−1,678	−2,200	−3,522	−3,468	−3,344

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: ICU vs RNXT FEMY vs RNXT IMDX vs RNXT

More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies

Figures from Renovorx, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Renovorx, Inc.